Elite Pharmaceuticals Inc (ELTP)

[lasers]

38 persons trial for pre Phase III planning Nov/Dec 2013 is expected to be a slam dunk success. Testing will be for ELI216 Oxy/Nal 2-bead ADT.

These results are expected to be as good or better then the 82 persons 2007/2008 Lifetree clinic trial by Dr. Lynn Webster.

Testing will be for:

(1) Normal ER of the 12 Hr agonist Oxycodone pain management when drug is taken normally,

(2) Rapid kill of euphoria by the sequestered antagonist Naltrexone release when drug is abused by crushing, sniffing, injecting etc,

(3) Long lasting Naltrexone sequestering ranging from 24 hrs up to 72 Hrs in the intestinal tract as may be experienced by OIC affected persons.

ELI216 family of drugs technology is expected to be

(i)FDA NDA505B2 approved with 3 years of FDA exclusivity and

(ii)Triple Patent Protected up to 2033.

Following the FDA 505B2 ELI216 Oxy/Nal approval, Elite is expected to follow with EL216 Mor/Nal which will be a "Better Embeda" Morphine.

More ELI216 agonists, both natural and synthetic, will follow such as Codeine and Hydromorphone, etc.

Patented also is the antagonist Naloxone such as used in Suboxone and could lead to another family of ELI216 ADT products as compared to Naltrexone.